middle.news

How Healius Turned Pathology Pressures into $7.9M EBIT and a $60M Defence Deal

8:26am on Wednesday 18th of February, 2026 AEDT Healthcare
Read Story

How Healius Turned Pathology Pressures into $7.9M EBIT and a $60M Defence Deal

8:26am on Wednesday 18th of February, 2026 AEDT
Key Points
  • 3.8% revenue growth to $688.1 million driven by Pathology and Agilex Biolabs
  • Underlying EBIT improved to $7.9 million from a prior loss
  • No interim dividend declared for the half-year
  • Signed a $60 million, five-year pathology services contract with the Australian Defence Force
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about HEALIUS (ASX:HLS)
OPEN ARTICLE